Sponsor:
Foundation for AIDS Vaccine
Research and Development
Cosponsors:
US National Institutes of Health
National Institute of Allergy
and Infectious Diseases
AIDS Vaccine
Research Center
HIV Vaccine Trials Network
Office of AIDS Research
National Cancer Institute
US Centers for Disease
Control and Prevention
UNAIDS and the World
Health Organization
Agence Nationale de
Recherches sur le SIDA, France
|
| |
 |
|
Thursday
|
Friday
|
Saturday
|
|
Time
|
September 5
|
September 6
|
September 7
|
September 8
|
 |
|
2. Plenary
Lessons from Acute
Infection and
Relevance to Vaccine Development [View Abstract]
Ashley Haase, Univ. of Minnesota,
Minneapolis, USA
|
54. Plenary
South Africa: A Case Study in Vaccine
Implementation
William Magkoba,
Med. Res. Council of South Africa, Cape Town
|
64. Plenary
Therapeutic Vaccines and Immune
Response
Bruce Walker,
Massachusetts Gen. Hosp., Harvard Med. Sch., Charlestown, USA
|
 |
|
3.
Plenary
Innate Immunity: The Toll-Like Receptor
Family [View Abstract]
Bruce Beutler, The Scripps Res. Inst.,
La Jolla, CA, USA |
55. Plenary
Lessons from the Monkey [View Abstract]
Norman Letvin, Harvard Med. Sch., Beth
Israel-Deaconess Med. Ctr., Boston, MA, USA |
65. Plenary
The
Genesis of HIV Diversity [View Abstract]
Paul
Sharp, Univ. of Nottingham, Queens Med. Ctr., UK
|
| |
|
<----------------------------- Coffee Break----------------------------->
|
 |
|
Slide Sessions
4. Candidate Vaccines I [View Abstracts]
Moderators: Frances Gotch, Imperial Coll. Sch. of Med., London, UK and Etienne Karita, Treatment and Res. AIDS Ctr., Kigali, Rwanda
5. Virology [View Abstracts]
Moderators: Francine McCutchan, Henry M. Jackson Fndn.,
Rockville, MD, USA and Larry Arthur, NCI, Frederick, MD, USA
6. Access and Implementation [View Abstracts]
Moderator: Jorge Beloqui, Group for Life Incentive (GIV), São Paulo, Brazil
7. Molecular Epidemiology [View Abstracts]
Moderator: Saladin Osmanov, WHO-UNAIDS Geneva, Switzerland
8. Novel Immune Responses [View Abstracts]
Moderators: Steven Harrison, Harvard Univ., Cambridge, MA, USA and
Frank Miedema, Univ. of Amsterdam/CLB, The Netherlands
9. Animal Models [View Abstracts]
Moderators: John Shiver, Merck Res. Labs, West Point, PA, USA and Harriet Robinson, Yerkes Reg. Primate Res. Ctr. of Emory Univ., Atlanta, GA, USA
10. Human Trials I [View Abstracts]
Moderator: John Mascola, NIAID Vaccine Res. Ctr., NIH, Bethesda, MD, USA
|
Slide Sessions
56. Innovative Approaches to HIV Vaccine Research: Highlighted NIAID Innovation Grants [View Abstracts]
Moderators: James Bradac, NIAID, NIH Bethesda, MD, USA and Jamie Scott, Simon Fraser Univ., Burnaby, BC, Canada
57. Candidate Vaccines II [View Abstracts]
Moderators: Deborah Birx, Walter Reed Army Inst. of Res., Rockville, MD, USA and Thomas Lehner, Guy's King's & St. Thomas' Hosp. Med. Sch., London, UK
58. Antibodies and Cytokines [View Abstracts]
Moderators: Peter Wright, Vanderbilt Univ. Med. Ctr., Nashville, TN, USA and Susan Zolla-Pazner, New York Univ. Sch. of Med., NY, USA
59. Human Trials II [View Abstracts]
Moderator: Raphael Dolin, Harvard Med. Sch., Boston, MA, USA
60. HIV Evolution [View Abstracts]
Moderator: Leopold Zekeng, Ministry of Hlth., Yaounde, Cameroon
61. Pathogenesis [View Abstracts]
Moderators: Françoise Barré-Sinoussi, Inst. Pasteur, Paris, France and Martin Markowitz, Aaron Diamond AIDS Res. Ctr., New York, NY, USA
|
10-11:30 am
66. Slide Session
Late Breakers [View
Abstracts]
Moderators:
Beatrice Hahn, Univ. of Alabama at Birmingham, USA and
Douglas Richman, Univ. of California, San Diego, USA
11:30 am-1 pm
67. Wrap-Up Session
and Summary Roundtable
AIDS
Vaccine 2003: The Future?
Convener: David Baltimore, California
Inst. of Technology, Pasadena
|
| |
|
<----------------------------- Lunch ----------------------------->
|
|
 |
|
11. Symposium
Novel Envelope Immunogens
[View Abstracts]
Conveners: Joseph Sodroski, Dana Farber
Cancer Inst., Boston, MA, USA and Carolyn Williamson, Univ. of Cape
Town, Observatory, South Africa
12. Symposium
Experiences with Clinical AIDS Vaccine Trials in
Humans: What We've Learned[View Abstracts]
Conveners: Larry
Corey, Univ. of Washington, Seattle and
HIV Vaccine Trials Network, USA
and Bette Korber, Los Alamos Natl. Lab., NM, USA
|
62. Symposium
Design, Oversight, and Review of
Phase III Efficacy Trials[View Abstracts]
Conveners: Tim Mastro, CDC, Atlanta, GA, USA
and Kachit Choopanya, Bangkok, Thailand
63. Symposium
Global Challenges for Vaccine
Implementation[View Abstracts]
Conveners:
Bill
Snow, AIDS Vaccine Advocacy Coalition, Berkley, CA, USA and Seth
Berkley, Intl. AIDS Vaccine Initiative, New York, NY, USA
|
|
|
|
Poster Sessions
All posters will be presented both Thursday and Friday
13.
T-Cell Epitope Mapping [View Abstracts]
14.
Mucosal Immune Responses [View Abstracts]
15.
Cytokines [View Abstracts]
16.
Cross-Clade Immune Responses [View Abstracts]
17.
CTL Escape [View Abstracts]
18.
Assay Development: CTL [View Abstracts]
19.
Assay Development: Neutralizing Antibodies [View Abstracts]
20.
Assay Development: Carbohydrate-Based Microarray [View Abstracts]
21.
Assay Development: Subtype Classifications [View Abstracts]
22.
Basic Virology [View Abstracts]
23.
Cellular Receptors [View Abstracts]
24.
Envelope Structure/Function/Novel Immunogens [View Abstracts]
25.
Acute Infection [View Abstracts]
26.
Determinants of HIV Disease Progression [View Abstracts]
27.
Susceptibility of HIV/SIV Infection [View Abstracts]
28.
NK Cell Activity [View Abstracts]
29.
HAART and Immune Responses [View Abstracts]
30.
Animal Models: Primates [View Abstracts]
31.
Animal Models: Mice [View Abstracts]
32.
Animal Models: Horses [View Abstracts]
33.
Animal Models: Rabbits [View Abstracts]
34.
DNA Vaccines [View Abstracts]
35.
Live-Attenuated Vaccines [View Abstracts]
36.
Whole Inactivated Virus Vaccines [View Abstracts]
37.
Dendritic Cell-Based Vaccines [View Abstracts]
38.
Synthetic Vaccines [View Abstracts]
39.
Peptide Immunogens [View Abstracts]
40.
Novel Vectors [View Abstracts]
41.
Pox Virus Vectors [View Abstracts]
42.
Adjuvants [View Abstracts]
43.
Safety and Immunogenicity: Phase I/II Trials [View Abstracts]
44.
Phase III Efficacy Trials [View Abstracts]
45.
Therapeutic Vaccination [View Abstracts]
46.
Database and Mathematical Modeling [View Abstracts]
47.
Epidemiology [View Abstracts]
48.
HIV Molecular Biology [View Abstracts]
49.
HIV-1 Subtypes [View Abstracts]
50.
HIV-1 Recombination [View Abstracts]
51.
Infrastructure Development [View Abstracts]
52.
Access and Implementation [View Abstracts]
|
|
 |
1. Opening
Session
Session Chairs:
David Baltimore, California
Inst. of Technology, Pasadena, USA and Salim Abdool-Karim, Univ. of Natal,
Durban, South Africa
Greetings from
Program Committee Chair, Beatrice Hahn, Univ. of Alabama at
Birmingham, USA
The Global Need For an AIDS
Vaccine
William Foege, Senior Hlth.
Advisor, Bill & Melinda Gates Fndn. and Rollins Sch. of Publ.
Hlth. of Emory Univ., Atlanta, GA, USA
NIAID and Vaccine Research: Science and
Policy [View Abstract]
Anthony Fauci, Director,
NIAID, NIH, Bethesda, MD, USA
Keynote Lecture:
AIDS in Africa
His Excellency Paul
Kagame
President, Republic of Rwanda
|
53.
Special
Workshop -
Orientation to Working with the U.S. Food and
Drug Administration
[View Abstracts]
|
|
|
|
Opening
Reception:
Pennsylvania Academy of Fine Arts
Broad
and Cherry Streets
(3 blocks from the Philadelphia
Marriott) |
|
|
|
|
|
